Campbell & CO Investment Adviser LLC Has $1.78 Million Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Campbell & CO Investment Adviser LLC raised its stake in ADMA Biologics Inc by 100.2%, now holding 89,844 shares valued at $1,783,000.
• Notable insider trading includes Director Jerrold B. Grossman selling 10,000 shares for $213,100, and Director Lawrence P. Guiheen selling 20,000 shares for $419,200, indicating decreasing positions among insiders.
• ADMA Biologics received a revised price target increase to $32.00 from Raymond James Financial, reflecting positive outlooks, while consensus ratings from analysts remain generally favorable.

Campbell & CO Investment Adviser LLC increased its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 100.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 89,844 shares of the biotechnology company's stock after purchasing an additional 44,957 shares during the period. Campbell & CO Investment Adviser LLC's holdings in ADMA Biologics were worth $1,783,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ADMA. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $35,000. SVB Wealth LLC acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $35,000. Smartleaf Asset Management LLC lifted its position in shares of ADMA Biologics by 161.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 1,493 shares during the last quarter. Tsfg LLC acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $51,000. Finally, Brooklyn Investment Group lifted its position in shares of ADMA Biologics by 28,655.6% during the 1st quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 2,579 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

Insiders Place Their Bets

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve Elms sold 194,749 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares in the company, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 455,621 shares of company stock valued at $9,461,633. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Price Performance

NASDAQ ADMA traded down $0.12 during trading hours on Friday, reaching $17.26. 2,527,726 shares of the company's stock were exchanged, compared to its average volume of 3,391,207. The stock has a market cap of $4.12 billion, a PE ratio of 20.07 and a beta of 0.54. ADMA Biologics Inc has a one year low of $13.50 and a one year high of $25.67. The firm has a fifty day moving average of $17.76 and a 200-day moving average of $18.93. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same quarter in the prior year, the business earned $0.13 EPS. The business's revenue for the quarter was up 13.8% compared to the same quarter last year. On average, equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.